Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA Approves Novartis AG's Seasonal Flu Vaccine-Reuters


Tuesday, 20 Nov 2012 06:13pm EST 

Reuters reported that The U.S. Food and Drug Administration said it has approved a seasonal flu vaccine produced by Novartis AG using animal cell culture rather than the traditional manufacturing using chicken eggs. The vaccine, to be sold by the Swiss drugmaker under the brand name Flucelvax, is approved to prevent season influenza in people aged 18 and over, the agency said. 

Company Quote

90.03
0.79 +0.89%
11:13am EDT